Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 4,691
Out of 5,162 analysts
8
Total ratings
11.11%
Success rate
-44.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $1.36 | +1,738.24% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $0.48 | +1,963.56% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $13.62 | -41.26% | 1 | Mar 11, 2024 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $30.86 | +172.20% | 1 | Aug 16, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $21.31 | +87.71% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $7.52 | +46.28% | 1 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $0.88 | +2,286.36% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $900 | $7.49 | +11,916.02% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $1.36
Upside: +1,738.24%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $0.48
Upside: +1,963.56%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $13.62
Upside: -41.26%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $30.86
Upside: +172.20%
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $21.31
Upside: +87.71%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $7.52
Upside: +46.28%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $0.88
Upside: +2,286.36%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $900
Current: $7.49
Upside: +11,916.02%